An Overview about Fibroblast Growth Factor 21 and Diabetic Kidney Disease

Abstract

Nephrologists around the world are aware of the growing prevalence of renal disease and the negative impact it has on public health. This emphasizes the need for novel therapeutic methods to slow progression and reduce consequences, as well as for early diagnosis to improve these outcomes. Endocrine fibroblast growth factor 21 (FGF21) has been discovered to regulate lipid, glucose, and energy homeostasis both locally and systemically. Also, FGF21 regulates stress responses by acting on the autonomic nervous system and the endocrine system. The pharmaceutical administration of FGF21 analogs has demonstrated encouraging outcomes in both dysmetabolic animal models and individuals with metabolic disorders. For almost a decade, researchers have examined how FGF21 affects the kidneys. Unfortunately, we know very little about how FGF21 works in the kidney. This article provides a brief overview of the biological effects of FGF21 and explores the link between this hormone and chronic kidney disease, highlighting key areas where more information is needed.